Patent intelligence · US
US 20260060930
New crystalline Forms, new pharmaceutical Composition and Dose Regimen of a Dipeptidyl peptidase I inhibitor for the Treatment of Patients with Bronchiectasis or other DPP-I mediated Diseases
New crystalline Forms, new pharmaceutical Composition and Dose Regimen of a Dipeptidyl peptidase I inhibitor for the Treatment of Patients w…
Patent details — US 20260060930
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 5, 2026
- Expiration
- Feb 28, 2046
- Applicant
- BOEHRINGER INGELHEIM INT [DE]
- CPC classes
- A61K 9/ 20 A I, A61K 9/ 28 A I, A61K 31/ 439 A I, A61K/31439
Quick answer
US 20260060930 (New crystalline Forms, new pharmaceutical Composition and Dose Regimen of a Dipeptidyl peptidase I inhibitor for the Treatment of Patients with Bronchiectasis or other DPP-I mediated Diseases) is held by BOEHRINGER INGELHEIM INT [DE]. Status: granted. Granted Mar 5, 2026. Expires Feb 28, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BOEHRINGER INGELHEIM INT [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 20 A I, A61K 9/ 28 A I, A61K 31/ 439 A I, A61K/31439, A61K/92018, A61K/92027
More from BOEHRINGER INGELHEIM INT [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2026114918
DÉRIVÉS DE 2-AMINO-3-CYANO THIOPHÈNE ANNELÉS SPIROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE KRAS POUR LE TRAITEMENT DU CANCER
granted -
WO 2026114957
DÉRIVÉS DE THIOPHÈNE 2-AMINO-3-CYANO SPIROCYCLIQUES ANNELÉS EN TANT QUE DÉGRADEURS DE KRAS POUR LE TRAITEMENT DU CANCER
granted -
US 20260146050
KRAS DEGRADING COMPOUNDS COMPRISING SPIROCYCLIC ANNULATED 2 AMINO-3-CYANO THIOPHENES
granted -
WO 2026109631
UTILISATION DE PROTÉINES ENGAGEANT LES LYMPHOCYTES T DANS LE TRAITEMENT DU CANCER
granted -
US 20260146049
SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER
granted -
WO 2026099754
MÉTHODE DE RÉDUCTION DE L'EXCRÉTION VIRALE, DE COLONISATION DE TISSU ET DE DÉPLÉTION LYMPHOÏDE PROVOQUÉES PAR OU ASSOCIÉES À UNE INFECTION PAR PCV2
granted -
US 20260116870
NOVEL NAV 1.1 POTENTIATORS
granted -
WO 2026082715
DÉPLÉTION DES MACROPHAGES ET VIRUS DE LA STOMATITE VÉSICULAIRE POUR LE TRAITEMENT DU CANCER
granted
Frequently asked questions
What is US patent 20260060930?
US 20260060930 (New crystalline Forms, new pharmaceutical Composition and Dose Regimen of a Dipeptidyl peptidase I inhibitor for the Treatment of Patients with Bronchiectasis or other DPP-I mediated Diseases) is held by BOEHRINGER INGELHEIM INT [DE]. Status: granted. Granted Mar 5, 2026. Expires Feb 28, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 20260060930?
BOEHRINGER INGELHEIM INT [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 20260060930 expire?
Our index shows an expiration date of Feb 28, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.